|
1
|
Caskey S, Moore JE, McCaughan J, Rendall JC. Belfast Agar–a simple laboratory medium to separate Pseudomonas aeruginosa from pan-resistant Burkholderia cenocepacia isolated from the sputum of patients with cystic fibrosis (CF). Br J Biomed Sci 2018. [DOI: 10.1080/09674845.2017.1411018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- S Caskey
- Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK
| | - JE Moore
- Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK
- Northern Ireland Public Health Laboratory, Department of Bacteriology, Belfast City Hospital, Belfast, UK
| | - J McCaughan
- Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK
- Department of Medical Microbiology, The Royal Group of Hospitals, Belfast, UK
| | - JC Rendall
- Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK
| |
Collapse
|
|
2
|
Loutet SA, El-Halfawy OM, Jassem AN, López JMS, Medarde AF, Speert DP, Davies JE, Valvano MA. Identification of synergists that potentiate the action of polymyxin B against Burkholderia cenocepacia. Int J Antimicrob Agents 2015; 46:376-80. [PMID: 26187366 DOI: 10.1016/j.ijantimicag.2015.05.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2015] [Revised: 04/19/2015] [Accepted: 05/11/2015] [Indexed: 10/23/2022]
Abstract
Burkholderia cenocepacia and other members of the Burkholderia cepacia complex (BCC) are highly multidrug-resistant bacteria that cause severe pulmonary infections in patients with cystic fibrosis. A screen of 2686 compounds derived from marine organisms identified molecules that could synergise with polymyxin B (PMB) to inhibit the growth of B. cenocepacia. At 1 μg/mL, five compounds synergised with PMB and inhibited the growth of B. cenocepacia by ≥70% compared with growth in PMB alone. Follow-up testing revealed that one compound from the screen, the aminocoumarin antibiotic novobiocin, synergised with PMB and colistin against tobramycin-resistant clinical isolates of B. cenocepacia and Burkholderia multivorans. In parallel, we show that novobiocin sensitivity is common among BCC species and that these bacteria are even more susceptible to an alternative aminocoumarin, clorobiocin, which also had an additive effect with PMB against B. cenocepacia. These studies support using aminocoumarin antibiotics to treat BCC infections and show that synergisers can be found to increase the efficacy of antimicrobial peptides and polymyxins against BCC bacteria.
Collapse
Affiliation(s)
- Slade A Loutet
- Centre for Human Immunology, Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada; Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada
| | - Omar M El-Halfawy
- Centre for Human Immunology, Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada; Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt
| | - Agatha N Jassem
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
| | | | | | - David P Speert
- Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada; Department of Pathology, University of British Columbia, Vancouver, BC, Canada
| | - Julian E Davies
- Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada
| | - Miguel A Valvano
- Centre for Human Immunology, Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada; Centre for Infection and Immunity, Queen's University Belfast, Belfast, UK.
| |
Collapse
|